Galectin Therapeutics Inc. · NASDAQ:GALT

Galectin Therapeutics — Technical Presentation (April 2018)

19 slides from Galectin Therapeutics's technical presentation, Apr 12, 2018

  1. Slide 1: The NASH-CX Trial: GR-MD-02 in NASH cirrhosis and portal hypertension

    A multicenter, randomized, double-blind, placebo-controlled trial of Galectin-3 inhibitor (GR-MD-02) for one year in patients with NASH cirrhosis and portal hypertension The NASH-CX Trial 1Naga Chalasani, 2Guadalupe Garcia-Tsao, 3Zachary Goodman, 4Eric Lawitz, 5Manal Abdelmalek, 6Mary Rinella, 7Mich

  2. Slide 2: Rationale for Galectin-3 Inhibition in NASH

    Rationale for Galectin-3 Inhibition in NASH ➢ Gal-3 is a lectin protein that binds to galactose residues on glycoproteins and is increased in NASH and liver Stellate Macrophage fibrosis/cirrhosis Cell ➢ Gal-3 null mice are resistant to NASH and fibrosis Gal-3 ➢ Gal-3 involved in multiple pathophysio

  3. Slide 3: NASH-CX Clinical Trial Design

    NASH-CX Clinical Trial Design AIM: Evaluate Safety and Efficacy of GR-MD-02 in Compensated NASH Cirrhosis NASH cirrhosis (biopsy) No decompensating event Major Inclusion Criteria HVPG ≥ 6 mmHg No or small varices Week 1 Week 54 n = 54 Placebo (PLB) n = 54 GR-MD-02 2 mg/kg (GR2) n = 54 GR-MD-02 8 mg/

  4. Slide 4: Study Endpoints & Assessment Methods

    Study Endpoints & Assessment Methods ➢ Primary Endpoint ▪ Change in Hepatic Venous Pressure Gradient (HVPG) • Baseline and Week 54 • Standardized Procedure and Central Blinded Reading ➢ Secondary Endpoints ▪ Change in Liver Histology • NAFLD Activity Score and Fibrosis Staging • Quantitative Morphom

  5. Slide 5: Study Disposition (36 US Sites)

    Study Disposition (36 US Sites) N = 290 Patients Screened N = 128 Screening Failures N = 162 No Varices = 81 Patients Randomized (1 withdrew before 1st dose) N = 54 N = 53 N = 54 Placebo (PLB) 2 mg/kg GR-MD-02 (GR2) 8 mg/kg GR-MD-02 (GR8) Discontinued Treatment = 3 Discontinued Treatment = 1 Discont

  6. Slide 6: Study Demographics & Baseline Assessments

    Study Demographics & Baseline Assessments Total Placebo GR2 GR8 (n=162) (n=54) (n=54) (n=54) Age, years; median (IQR) 59 (52, 65) 59 (53, 64) 60 (53, 65) 58 (51, 63) Female, n (%) 113 (70) 36 (67) 34 (63) 43 (79) Non-Hispanic White, n (%) 132 (81) 46 (85) 46 (85) 40 (74) BMI, kg/m2; median (IQR) 34

  7. Slide 7: Baseline HVPG (mmHg) in Patient Groups

    Baseline HVPG (mmHg) in Patient Groups Total Placebo GR2 GR8 Mean ± SD (n) Mean ± SD (n) Mean ± SD (n) Mean ± SD (n) Full Analysis Set 12.2 ± 4.2 (162) 11.6 ± 4.0 (54) 12.4 ± 4.3 (54) 12.7 ± 4.2 (54) CSPH Sub-group 14.3 ± 3.4 (108) 14 ± 3.1 (33) 14.2 ± 3.9 (37) 14.8 ± 3.1 (38) MPH Sub-Group 7.9 ± 1.

  8. Slide 8: HVPG Primary Endpoint (Pre-Specified Analyses)

    HVPG Primary Endpoint (Pre-Specified Analyses) Total Patient Population Mild Portal Hypertension mean ± SEM mean ± SEM ITT with LOCF (last observation carried forward); ANOVA with LSD (least squared difference)

  9. Slide 9: No Esophageal Varices at Baseline (Post Hoc Analysis)

    No Esophageal Varices at Baseline (Post Hoc Analysis) 50% of patients (81) did not have varices at baseline mean ± SEM ITT with LOCF; ANOVA with LSD

  10. Slide 10: Responder Analysis (Post Hoc Analysis)

    Responder Analysis (Post Hoc Analysis) Percentage of Patients Who Had a Clinically Relevant Reduction in HVPG With: • ≥ 2 mmHg Decrease From Baseline AND • ≥ 20% Decrease From Baseline Chi Square Analysis

  11. Slide 11: PK-PD Correlation Between Human and Mouse Data

    PK-PD Correlation Between Human and Mouse Data AUC of patients in NASH- CX (µg*hr./mL) 1Traber, P.G. and E. Zomer, Therapy of experimental NASH and fibrosis with galectin inhibitors. PLoS. One, 2013. 8(12): p. e83481.

  12. Slide 12: Change in HVPG Using PK Range Groups for GR8

    Change in HVPG Using PK Range Groups for GR8 mean ± SEM ITT; ANOVA with LSD; AUC=area under concentration curve (µg*hr./mL)

  13. Slide 13: Changes in Liver Histology in Total Patient Population

    Changes in Liver Histology in Total Patient Population ➢ Trend towards improvement in NAS that did not reach significance ➢ No differences in steatosis across the treatment groups ➢ Statistically significant difference between GR2 and placebo for inflammation scores in the patients without baseline

  14. Slide 14: Correlation of Liver Biopsy Findings in HVPG Responders

    Correlation of Liver Biopsy Findings in HVPG Responders Total Patient Population GR21 GR81 Hepatocyte Ballooning 0.04 0.05 NAFLD Activity Score 0.19 0.28 Ishak Stage 0.20 0.59 1p value compared to placebo Ordinal logistic regression analysis was used to compare groups. ITT analysis set.

  15. Slide 15: Fewer Patients in GR Groups Developed New Varices

    Fewer Patients in GR Groups Developed New Varices Chi Square Analysis

  16. Slide 16: Development of Cirrhosis Complications

    Development of Cirrhosis Complications1 Total PLB GR2 GR8 FAS Population n=161 n=54 n=53 n=54 • Complications – n(%) 21 (13) 9 (17) 5 (9) 7 (13) No-Varices Population n=81 n=33 n=25 n=23 • Complications – n(%) 12 (15) 7 (21) 3 (12) 2 (9) MPH Population n=53 n=21 n=16 n=16 • Complications – n(%) 4 (8

  17. Slide 17: Adverse Events

    Adverse Events Total PLB GR2 GR8 (n=161) (n=54) (n=53) (n=54) Treatment Emergent (TE) AEs 1323 431 509 383 Patients with at least ≥ grade 3 AE (%) 33 (20.5) 11 (20.4) 11 (20.8) 11 (20.4) Patients with at least 1 TE SAE1 (total) 25 (34) 8 (10) 5 (10) 12 (14) Study drug discontinued due to AE 3 0 0 32

  18. Slide 18: Conclusions

    Conclusions ➢ Change in HVPG associated with GR treatment was not significant in total patient population, but statistically significant in the pre-specified group of mild portal hypertension ➢ In patients without varices at baseline, there was a statistically significant difference in the GR2 group

  19. Slide 19: Acknowledgements

    Acknowledgements We extend our thanks to the patients, their families and all participating investigators This study was funded by Galectin Therapeutics, Inc.

Galectin Therapeutics — Technical Presentation (April 2018) on 6ix